Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray ...
LTR Pharma recently announced the dosing of the first patients in the Phase II study of SPONTAN ®, which is evaluating the ...
REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENTSARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE ...
The global nasal drug delivery technology market is projected to grow at a CAGR of approximately 7% over the next five years.
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal ...
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC:BLEG), a leader in innovative addiction treatment and harm reduction solutions, today announced that ...
All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only ...
Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development ...
NeOnc, a biotech company helmed by Dr. Thomas Chen, brings the first non-invasive intranasal drug delivery for brain cancer into the spotlight. With this revolutionary treatment, NeOnc is poised to ...
Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results